The acquisition will add 20,000 litres of installed biologics drug substance manufacturing capacity for Syngene
Reports revenue growth of 9% to INR 882 crores in Q2 FY24
2023 Nobel laureates discovered how pseudouridine could make mRNA suitable for vaccines
Three block copolymers added to RESOMER portfolio of bioabsorbable polymers
Multi-million dollar investment augments in-vitro biology capabilities in primary and secondary screening
The new gummy capabilities include a dedicated R&D lab, an automated production line, and bottle packaging solutions
New Board of Directors and management team at Suven Pharma also appointed
The product is expected to start contributing meaningfully to the revenue from FY25
The company has received the Establishment Inspection Report (EIR) from the USFDA for the Pre-Approval Inspection (PAI) at a manufacturing site situated at Savli, Vadodara, Gujarat, with Zero 483 observations
Subscribe To Our Newsletter & Stay Updated
